Cipher Pharmaceuticals Inc. (TSE:CPH – Free Report) (NASDAQ:CPHR) – Equities researchers at Leede Financial decreased their FY2025 earnings estimates for Cipher Pharmaceuticals in a report released on Wednesday, March 19th. Leede Financial analyst D. Loe now expects that the company will post earnings per share of $0.87 for the year, down from their previous forecast of $0.93. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals’ FY2026 earnings at $1.00 EPS.
Cipher Pharmaceuticals Stock Up 0.3 %
Shares of TSE:CPH opened at C$13.49 on Friday. The company has a quick ratio of 2.67, a current ratio of 2.00 and a debt-to-equity ratio of 41.22. Cipher Pharmaceuticals has a 52-week low of C$7.90 and a 52-week high of C$19.69. The company has a 50 day moving average of C$12.93 and a two-hundred day moving average of C$14.53. The company has a market capitalization of C$242.19 million, a price-to-earnings ratio of 14.90 and a beta of 1.20.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.
See Also
- Five stocks we like better than Cipher Pharmaceuticals
- How to Find Undervalued Stocks
- 4 Undervalued Growth Stocks to Buy and Hold for the Long Term
- Ride Out The Recession With These Dividend Kings
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- There Are Different Types of Stock To Invest In
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
